Comparing App Therapeutics (NASDAQ:APLT) and Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S ( NASDAQ:ASND – Get Your Free Report ) and Applied Therapeutics ( NASDAQ:APLT – Get Your Free Report ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and risk

Ascendis Pharma A/S has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.99, indicating that that its stock price is 99% more volatile than the S&P 500. .

Earnings and Rating

This table compares Ascendis Pharma A/S and Applied Therapeutics’ gross revenue, earnings per share and valuation.

Applied Therapeutics has lower revenue but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst recommendations

This is a breakdown of current recommendations and price targets for Ascendis Pharma A/S and Applied Therapeutics, provided by MarketBeat.com.

Ascendis Pharma A/S currently has a consensus price target of $187.08, suggesting a potential upside of 57.01%. Applied Therapeutics has a consensus target price of $11.25, suggesting a potential upside of 97.37%. Given Applied Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Ascendis Pharma A/S.

Institutional and insider ownership

98.3% of Applied Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 8.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and big money managers believe a stock will outperform the market over the long term.

return

This table compares Ascendis Pharma A/S and Applied Therapeutics’ net margins, return on equity and return on assets.

Summary

Applied Therapeutics beats Ascendis Pharma A/S in 9 of the 14 factors compared between the two stocks.

About Ascendis Pharma A/S

(Get a free report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. Provides SKYTROFA to treat patients with growth hormone deficiency (GHD). The company is also developing a series of three independent endocrinology rare disease product candidates in clinical development, as well as focusing on advancing oncology therapeutic candidates. The company was founded in 2006 and is based in Hellerup, Denmark.

About Applied Therapy

(Get a free report)

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in the development of a range of novel product candidates against validated molecular targets in unmet medical need indications in the United States. The company’s lead product candidate is AT-007 (also called govorestat), which completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in the pediatric clinical trial for the treatment of galactosemia in children, for the treatment of the enzyme sorbitol dehydrogenase and for the treatment of the enzyme phosphomannomutase- CDG. It is also developing AT-001 (also called caficrestat) which is in phase 3 clinical trials to treat diabetic cardiomyopathy as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment of diabetic retinopathy. The Company has an exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Receive daily news and ratings for Ascendis Pharma A/S – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ascendis Pharma A/S and related companies with MarketBeat.com’s FREE daily email newsletter .